



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Zepatier[®] Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Chronic hepatitis C virus (HCV)					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical Information:					
Document the patient's HCV genotype: _____					
Select if Zepatier is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Gastroenterologist		<input type="checkbox"/> HIV specialist certified through the American Academy of HIV Medicine			
<input type="checkbox"/> Hepatologist		<input type="checkbox"/> Infectious disease specialist			
Will the patient use Zepatier in combination with ribavirin? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have moderate to severe hepatic impairment (e.g., Child-Pugh Class B or C)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if the patient has history of trial and failure, contraindication, or intolerance to the following:					
<input type="checkbox"/> Epclusa, sofosbuvir/velpatasvir		<input type="checkbox"/> Mavyret (glecaprevir/pibrentasvir)			
<input type="checkbox"/> Harvoni, ledipasvir/sofosbuvir		<input type="checkbox"/> Vosevi (sofosbuvir/velpatasvir/voxilaprevir)			
Is this for continuation of prior Zepatier therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For genotype 1, also answer the following:					
Select the patient's treatment experience:					
<input type="checkbox"/> Treatment-naïve					
<input type="checkbox"/> Prior failure to peginterferon alfa plus ribavirin treatment					
<input type="checkbox"/> Prior failure to treatment with peginterferon alfa plus ribavirin plus a HCV NS3/4A protease inhibitor (e.g., boceprevir, sim eprevir, or telaprevir)					
Has the patient been tested for the presence of NS5A resistance-associated polymorphisms? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If "yes" to the above question, does the patient have baseline NS5A resistance-associated polymorphisms (i.e., polymorphisms at amino acid positions 28, 30, 31, or 93)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For genotype 4, also answer the following:					
Is the patient treatment-naïve? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient experienced prior viral relapse with peginterferon alfa plus ribavirin treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient had prior on-treatment virologic failure (failure to suppress or viral breakthrough) to peginterferon alfa plus ribavirin treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Zepatier_CMS_2019Feb-W



Zepatier[®] Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Quantity Limit:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- Titration or loading-dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- There is a medically necessary justification why the patient cannot use a higher commercially available strength to achieve the same dosage and remain within the same dosing frequency. **Please specify:** _____
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.